SCHEMBL2301256

SCHEMBL2301256

c1ccc(OC2C[N]C2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 2/20 0.52
SLC6A2 P23975 5/20 0.48
SLC6A3 Q01959 5/20 0.48
SLC6A4 P31645 3/20 0.48
NAAA Q02083 1/20 0.42
CARM1 Q86X55 1/20 0.39
PRMT6 Q96LA8 1/20 0.39
LTA4H P09960 1/20 0.38
TSHR P16473 1/20 0.38
HTR1A P08908 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA7 P36544 1/20 0.37
CHRNA4 P43681 1/20 0.37
CHRNA10 Q9GZZ6 1/20 0.37
CHRNA9 Q9UGM1 1/20 0.37
DRD2 P14416 3/20 0.36
DRD4 P21917 3/20 0.36
DRD3 P35462 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL242185 0.83 HRH1 (0.50) HRH1SLC6A2SLC6A3SLC6A4NAAA
SCHEMBL2299962 0.82 SLC6A2 (0.43) SLC6A2SLC6A3SLC6A4NAAALTA4H
SCHEMBL3169151 0.80 HRH1 (0.47) HRH1SLC6A2SLC6A3SLC6A4NAAA
SCHEMBL4971365 0.80 HRH1 (0.47) HRH1SLC6A2SLC6A3SLC6A4NAAA
SCHEMBL2302743 0.77 SLC6A4 (0.52) SLC6A2SLC6A3SLC6A4
SCHEMBL3125920 0.77 ACHE (0.41) NAAATSHR
SCHEMBL2302199 0.77 EPHX2 (0.41) NAAA
SCHEMBL2299147 0.77 CA1 (0.48) GAA
SCHEMBL240230 0.77 HRH1 (0.59) HRH1SLC6A2SLC6A3SLC6A4CARM1
SCHEMBL29856 0.77 HRH1 (0.71) HRH1SLC6A2SLC6A3SLC6A4CARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010022055-A2 INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2010-02-25 WO claimed
US-9334269-B2 Carboxamides as inhibitors of voltage-gated sodium channels AMGEN INC. (US) 2016-05-10 US disclosed
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2013-05-23 US disclosed
EP-2536689-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN Amgen Inc. (US) 2012-12-26 EP disclosed
WO-2011103196-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN AMGEN INC. (US) 2011-08-25 WO disclosed
WO-2010022055-A2 INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS CACNA1B, SCN1A, CACNA1I HRH1 1289/4885SLC6A2 475/4885SLC6A3 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.